Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.62 |
| ▸ | GSK3B | P49841 | 2/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987081 | 0.85 | PTPN1 (0.75) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL6419173 | 0.84 | PTPN1 (0.60) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL1350296 | 0.80 | CES2 (0.57) | CES2HDAC1SRD5A2ALDH1A1MAPT | |
| SCHEMBL1643579 | 0.79 | PTPN1 (0.73) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL6168439 | 0.79 | PLOD2 (0.56) | PTPN1CES2CES1HSD11B1ALDH1A1 | |
| SCHEMBL14504336 | 0.79 | PTPN1 (0.50) | PTPN1ALDH1A1MAPT | |
| SCHEMBL31465822 | 0.78 | PLOD2 (0.58) | ALDH1A1PLOD2 | |
| SCHEMBL3569892 | 0.78 | PTPN1 (0.66) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL313164 | 0.78 | PLOD2 (0.70) | PTPN1GSK3BMMP1CES2CES1 | |
| SCHEMBL22130998 | 0.78 | PTPN1 (0.71) | PTPN1GSK3BMMP1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349844-B2 | Substituted pyrazolo [1,5-A] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GATTI MCARTHUR SILVIA (CH) | 2012-02-16 | — | — | US | disclosed |
| US-8093263-B2 | Substituted pyrazolo [1,5-a] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8063048-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-1851225-B1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-1670801-B1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-20100210642-A1 | ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES | GATTI MCARTHUR SILVIA | 2010-08-19 | — | — | US | disclosed |
| US-7718661-B2 | Acetylenyl-pyrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| EP-1934214-B1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-04-07 | — | — | EP | disclosed |
| EP-1863818-B1 | ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-03-10 | — | — | EP | disclosed |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | US | disclosed |
| US-20050130992-A1 | Pyrazolo-pyridine | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | US | disclosed |
| WO-2005040171-A1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-5753688-A | ANTIINFLAMMATORY | TALLEY JOHN J (US) | 1998-05-19 | — | — | US | disclosed |
| US-5521207-A | Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation | G.D. SEARLE & CO. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5516907-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-05-14 | — | — | US | disclosed |
| US-5510496-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5508426-A | ANTIARTHRITIC AGENT | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5504215-A | Substituted pyrazolyl benzenesulfonamide compounds for the treatment of inflammation | G. D. SEARLE & CO. (US) | 1996-04-02 | — | — | US | disclosed |
| US-5466823-A | Antiinflammatory agents; FDA Orange book listed patent for Celebrex | G.D. SEARLE & CO. (US) | 1995-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210642-A1 | ACETYLENYL-PYRAZOLO-PYRIMIDINE DERIVATIVES | NAT1, TPMT, ACAT1 | PTPN1 3947/4885GSK3B 2711/4885MMP1 4829/4885 |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | P2RX3, P2RX1, P2RX5 | PTPN1 1042/4885GSK3B 3482/4885MMP1 4657/4885 |
| US-20050130992-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | PTPN1 1231/4885GSK3B 3495/4885MMP1 4762/4885 |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GRM1, GRM2, GRM3 | PTPN1 1498/4885GSK3B 4519/4885MMP1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.